Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2006-05-23
2006-05-23
Gitomer, Ralph (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S026000
Reexamination Certificate
active
07049058
ABSTRACT:
Disclosed are methods for suppressing the induction of inducible nitric oxide synthase in a cell comprising contacting said cell with an effective amount of at least one induction suppressor of inducible nitric oxide synthase or a cytokine are disclosed. The induction suppressor can be an inhibitor of mevalonate synthesis, an inhibitor of the farnesylation of Ras, an antioxidant, an enhancer of intracellular cAMP, an enhancer of protein kinase A (PKA), an inhibitor of NF-kβ activation, an inhibitor of Ras/Raf/MAP kinase pathway, an inhibitor of mevalonate pyrophosphate decarboxylase or an inhibitor of farnesyl pyrophosphate.
REFERENCES:
patent: 5118601 (1992-06-01), Gruber
patent: 5286895 (1994-02-01), Harris et al.
patent: 5912019 (1999-06-01), Singh
patent: 5965553 (1999-10-01), Bell et al.
patent: 5968983 (1999-10-01), Kaesemeyer
patent: 6080778 (2000-06-01), Yanker et al.
patent: 6147109 (2000-11-01), Liao et al.
patent: 6204248 (2001-03-01), Demopoulos et al.
patent: 6552075 (2003-04-01), Gribble et al.
patent: 6605729 (2003-08-01), Byrn et al.
patent: 6673831 (2004-01-01), Tobert
patent: WO93/14749 (1993-08-01), None
patent: WO 93/14749 (1993-08-01), None
patent: WO95/06470 (1995-03-01), None
Boese M. Effect of Cyclic GMP Dependent Vasodilators on the Expression of Inducible Nitric Oxide Synthase in Vascular Smooth Muscle Cells: Role of cAMP. British J of Pharmacology 1996 119(4)707-715.
Sherman M. Pyrrolidine Dithiocarbamate Inhibits Inductionof Nitric Oxide Synthase Activity in Ral Alveolar Macrophages. Biochemical and Biophysical Research Communications. 1993 191(3)1301-1308.
Bedoya F. Pyrrolidine Dithiocarbamate Prevents IL-1 Induced Nitric Oxide Synthase mRNA, But Not Superoxide Dismutase mRNA, in Insulin Producing Cells. Biochemical and Biophysical Research Communications. 1995 210(3)816-822.
Pahan K. Increasing cAMP Attenuates Induction of Inducible Nitric Oxide Synthase in Rat Primary Astrocytes. J of Biological Chemistry Mar. 1997 272(12)7786-7791.
Paul A. Differential Regulation by Protein Kinase C Isoforms of Nitric Oxide Synthase Induction in RAW 264.7 Macrophages and Rat Aortic Smooth Muscle Cells. British J of Pharmacology 1997 120(5)940-946.
Sparks, “Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease?”Ann. N.Y. Acad. Sci.,826:128-146, 1997.
Ongini et al., “Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties,”Proc. Natl. Acad. Sci., USA,101(22):8497-8502, 2004.
“Nymox pursuing new approaches to fighting Alzheimer's disease,”Business Wire,Jul. 2, 2004.
“Statins-the next miracle drug? Beyond cholesterol lowering,”Clinician Reviews,14(6):84(3), Jun. 1, 2004.
Cuzzocrea et al., “Beneficial effects of n-acetylcysteine on ischemic brain injury,”British Journal of Pharmacology,130:1219-1226, 2000.
Fukuzawa et al., “N-acetylcysteine ameliorates reperfusion injury after warm hepatic ischemia,”Transplantation,59(1):6-9, 1995.
Galinanes et al., “Sustained protection by acadesine against ischemia- and reperfusion-induced injury: Studies in the transplanted rat heart,”Circulation,86(2):589-611, 1992.
Hashimoto et al., “5-amino-4-imidazolecarboxamide riboside confers strong tolerance to glucose starvation in a 5′-AMP-activated protein kinase-dependent fashion,”Biochemical and Biophysical Research Communications,290:263-267, 2002.
Knuckey et al., “N-acetylcysteine enhances hippocampal neuronal survival after transient forebrain ischemia in rats,”Stroke,26:305-311, 1995.
Menasche et al., “Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting,”Journal of Thoracic and Cardiovascular Surgery,110(4):1096-1106, 1995.
Sochman et al., “Infarct size limitation: acute N-acetylcysteine defense (ISLAND trial): preliminary analysis and report after the first 30 patients,”Clin Cardiol,19:94-100, 1996.
Weigland et al., “N-acetylcysteine attenuates the increase in α-glutathione S-transferase and circulating ICAM-1 and VCAM-1 after reperfusion in humans undergoing liver transplantation,”Transplantation,72(4):694-698, 2001.
Miller and Chacko, “The role of cholesterol and statins in Alzheimer's Disease,”Annals of Pharmacotherapy,38:91-98, 2004.
Horwich et al., “Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure,”J. Am. College of Cardiol.,43(4):642-548, 2004.
Jukema et al., “Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels,”Circulation,91:2528-2540, 1995.
Sacks et al., “The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels,”New Engl. J. Med.,335(14):1001-1009, 1996.
Stüve et al., “The potential therapeutic role of statins in central nervous systems autoimmune disorders,”Cell. Mol. Life Sci.,60:2483-2491, 2003.
Co-pending U.S. Appl. No. 10/429,231 filed May 2, 2003.
Co-pending U.S. Provisional Appl. No. 60/531,828, filed Dec. 23, 2003.
Co-pending U.S. Provisional Appl. No. 60/559,112, filed Apr. 2, 2004.
Giri et al., “5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase,”J. Neuroscience,24(2):479-487, 2004.
Zamrini et al., “Association between statin use and Alzheimer's disease,”Neuroepidemiology,23:94-98, 2004.
Abud-Mendoza et al., “Therapy with statins in patients with refractory rheumatic diseases: a preliminary study,”Lupus,12(8):607-611, 2003.
Leung et al., “A novel anti-inflammatory role for simvastatin in inflammatory arthritis,”Journal of Immunology,170(3):1524-1530, 2003.
Terkeltaub et al., “Role of the mevalonate pathway of isoprenoid synthesis IL-8 generation by activated monocytic cells,”J. Leukoc. Biol.,55(6):749-755, 1994.
Amerongen et al., “Simvastatin improves disturbed endothelial barrier function,”Circulation,102:2803-2809, 2000.
Baughman, “Dopamine-transporter density in patients with ADHD,”The Lancet,355:1460-61, 2000.
Bellosta et al., “Direct vascular effects of HMG-CoA reductase inhibitors,”Atheroscl.,137:S101-109, 1998.
Bellosta et al., “Non-lipid related effects of statins,”Ann. Med.,32:164-176, 2000.
Bowen and Guyton, “Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol,”Current Science,2:58-63, 2000.
Buemi et al., “Effect of fluvastatin on proteinuria in patients with immunoglobin A nephropathy,”Clin. Phar.&Therapeutics,67:427-431, 2000.
Casey et al., “p21ras is modified by a farnesyl isoprenoid,”Proc. Natl. Acad. Sci.,86:8323-27, 1989.
Ortego et al., “Atorvastatin reduces NF-κK activation and chemokine expression in vascular smooth muscle cells and mononuclear cells,”Atherosclerosis,147:253-261, 1999.
Romano et al., “Inhibition of monocyte chemotactic protein-1 synthesis by statins,”Lab. Investigation,80:1095-1100, 2000.
Sinensky et al., “Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis,”J. Biol. Chem.,265:19937-19941, 1990.
Toledano and Patridge, “Statins: not just for cholesterol?”TEMvol. 11:255-256, 2000.
Vaughan and Delanty, “Neuroprotective properties of statins in cerebral ischemia and stroke,”Stroke,30:1969-1973, 1999.
Vaughan et al., “Statins do more than just lower cholesterol,”The Lancet,348:1079-1082, 1996.
Wolozin et al., “Decreased prevalence of alzheimer disease associated with 3-Hydroxy-3-Methylglutaryl Coenzyme A reductase inhibitors,&#
Fulbright & Jaworski L.L.P.
Gitomer Ralph
MUSC Foundation for Research Development
LandOfFree
Methods for suppressing the induction of nitric oxide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for suppressing the induction of nitric oxide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for suppressing the induction of nitric oxide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3634317